|
|
|
|
Direct Cost |
Indirect Cost |
|
261201200021I-0-26100006-1 |
HHSN261201200020I/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Task Order Title: Evaluation on the Prevention by Actoplus/Met (Pi |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NCI |
|
|
$489,093 |
261201200021I-0-26100007-1 |
HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NCI |
|
|
$545,105 |
272201100016I-0-27200006-1 |
Task B15: In Vitro Assessments Program - Collaborative Antiviral Testing Group |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$1,082 |
272201100016I-0-27200007-1 |
Task B16: Comprehensive Virology Panel |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$77,914 |
272201100016I-0-27200007-2 |
Task B16: Comprehensive Virology Panel |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$1,065,286 |
272201100034C-2-0-1 |
Targeted Clinical Research Program to Address Selected Viral Infections |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$1,246,266 |
272201300012I-0-27200003-1 |
Phase II Trial of Therapeutics for Neisseria Gonorrhoeae - STICTG |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$1,255,296 |
272201300012I-0-27200004-1 |
Development of Diagnostics for Neisseria Gonorrhoeae - STICTG |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$467,698 |
272201300012I-0-27200005-1 |
Development of Diagnostics for Chlamydia Trachomatis - STICTG |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$123,889 |
272201300012I-0-27200006-1 |
Sexually Transmitted Infections Clinical Trials Group |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
|
|
$829,430 |
275201300014C-2-0-1 |
ASTHMA CONTROL VARIABILITY DURING PREGNANCY |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NICHD |
|
|
$5,645 |
1F31AI104172-01A1 |
Hydrogen Peroxide and Capsule Production in Streptococcus pneumoniae |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
$32,573 |
|
$32,573 |
1F31AI106288-01A1 |
Regulation of Vibrio Biofilm Formation by H-NS Repression and Anti-repression. |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIAID |
$32,573 |
|
$32,573 |
1F31CA176955-01A1 |
Novel Role for Shed Syndecan 1 in Promoting an Aggressive Tumor Phenotype |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NCI |
$34,171 |
|
$34,171 |
1F31DA037106-01 |
Substance Abuse Stigma and Engagement in HIV Care: A Mixed Methods Investigation |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIDA |
$32,743 |
|
$32,743 |
1F31NS084683-01A1 |
GIRK channel modulation of SCN excitability and circadian rhythms |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NINDS |
$30,996 |
|
$30,996 |
1F31NS084722-01A1 |
Role of microRNAs in modulating inflammation in alpha-syn mediated models of PD |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NINDS |
$32,782 |
|
$32,782 |
1F32HL121924-01 |
Oxidative stress and T cell balance: Effect on pulmonary tuberculosis during HIV |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NHLBI |
$59,594 |
|
$59,594 |
1K01DK098319-01A1 |
Duodenal nutrient exclusion enhances glucose metabolism via CNS regulation |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIDDK |
$140,740 |
$11,259 |
$151,999 |
1K01DK101681-01A1 |
Optogenetic dissection of the functional properties of bladder afferent populations |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
NIDDK |
$122,472 |
$9,798 |
$132,270 |